Phase 3 N=51 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Eosinophilic Esophagitis · Gastroesophageal Reflux Disease · EE
Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=572 Reflux Esophagitis Phase III Study (Initial Treatment)
Reflux Esophagitis
Primary: Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los…
N/A N=42 Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants Who Responded — 7; 4 participants
Phase 3 N=564 Reflux Esophagitis Phase III Study (Maintenance Treatment)
Reflux Esophagitis
Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants
Phase 4 N=208 Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety
Erosive Esophagitis
Primary: Number of Participants With Malignant Alteration of Epithelial Cells — 0; 0 Participants
Phase 3 N=26 A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
Non-erosive Gastroesophageal Reflux Disease
Primary: The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period…
Phase 3 N=337 Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
Refractory Reflux Esophagitis
Primary: Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N) — 58.8; 78.4; 77.0 Percentage of…
Phase 2 N=248 A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
Erosive Esophagitis
Primary: Number of Patients With Esophageal Mucosa Healing — 28; 28; 32; 18 Participants
Phase 3 N=1,027 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis
Erosive Esophagitis
Primary: Healing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 8 — 92.9; 84.6 percentage of participants — p=<0.0001
Phase 4 N=305 Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
Non Erosive Reflux Disease · Chronic Gastritis
Primary: Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. — 94.9; 87.3 percentage of participants
Phase 3 N=288 A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
Non-erosive Gastroesophageal Reflux Disease
Primary: Percentage of Participants With Complete Relief of Heartburn at Final Evaluation — 20.9; 34.4; 43.6 Percentage of participants
Phase 3 N=318 A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved
Eosinophilic Esophagitis (EoE)
Primary: Number of Participants With Histologic Response at the Final Treatment Period Evaluation (Week 16) — 1; 113; 104; 100 Participants — p=<0.001
Phase 3 N=445 Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis
Esophagitis, Reflux · Esophagitis, Peptic
Primary: Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis. — 14.3; 66.4; 66.4 Percentage of Subjects…
Phase 3 N=451 Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis
Esophagitis, Reflux · Esophagitis, Peptic
Primary: Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis. — 14.3; 66.4; 64.5 Percentage of Subjects…
Phase 2 N=308 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis
Primary: Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) — 10; 19; 14; 16 Participants — p=0.001
Phase 3 N=481 Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis
Erosive Esophagitis
Primary: Percentage of Participants With Endoscopic Healing of Erosive Esophagitis During the 8-Week Treatment Phase — 92.4; 91.3 percentage of participants
Phase 2 N=42 Topical Steroid Treatment for Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants With Complete Response to Dysphagia — 9; 6 participants — p=0.74
Phase 3 N=1,055 Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD)
Primary: Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks — 75; 80; 20.3; 14.9 Percentage…
Phase 4 N=408 Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy
Erosive Esophagitis
Primary: The Rates of Complete Symptom Relief — 152; 157 participants — p=<0.05
Phase 3 N=2,038 Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Esophagitis, Reflux · Esophagitis, Peptic
Primary: Percentage of Subjects With Complete Healing of Erosive Esophagitis (EE) by Week 8 as Assessed by Endoscopy - Crude Rate Analysis. — 85.3; 85.8; 79.0 Percentage of…
Phase 2 N=119 OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension
Eosinophilic Esophagitis (EoE)
Primary: Percent of Participants Who Were Histologic Responders — 2.6; 38.8 percent of participants — p=<0.0001
Phase 3 N=2,054 Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Esophagitis, Reflux · Esophagitis, Peptic
Primary: Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis. — 86.9; 89.4; 84.6 percentage of subjects…
Phase 3 N=451 Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
Esophagitis, Reflux · Esophagitis, Peptic
Primary: Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis. — 14.3; 66.4; 64.5 Percentage of Subjects…
Phase 2 N=36 A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Change From Baseline in the Peak Esophageal Intraepithelial Eosinophil Count at Week 4 (Mean) — -9.2; -31.6; -7.8 eosinophil count per high power field
Phase 3 N=1,065 Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD)
Primary: Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks — 78.4; 77.5; 16.6; 18.4…
N/A N=1,995 Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)
Gastroesophageal Reflux Disease
Primary: Patient's Assessment of General Well-being During the Last 24 Hours (Diaries; ReQuest™ in Practice) — 5.31; 4.60; 3.67; 2.95 Units on a scale
Phase 3 N=287 Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
Refractory Reflux Esophagitis
Primary: Percentage of Participants With Healing of RE Who Were Graded "O" at Week 8 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles…
Phase 3 N=340 Efficacy of Esomeprazole in Patients With Frequent Heartburn
Heartburn
Primary: Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment — 43.32; 29.44 Percentage
Phase 3 N=341 Efficacy of Esomeprazole in Patients With Frequent Heartburn
Heartburn
Primary: Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment — 46.79; 30.93 Percentage of heartburn free days
N/A N=18 Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis
Eosinophilic Gastroenteritis
Primary: Percent of Participants in Complete Histologic Remission — 100 percentage of participants